The following discussion of our financial condition and results of operations
should be read in conjunction with the unaudited condensed consolidated
financial statements and notes to those statements included elsewhere in this
Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 and with our
audited consolidated financial statements for the year ended June 30, 2021
included in our Annual Report on Form 10-K, filed with the Securities and
Exchange Commission on September 28, 2021.
This Quarterly Report on Form 10-Q contains forward-looking statements. When
used in this report, the words anticipate, suggest, estimate, plan, project,
continue, ongoing, potential, expect, predict, believe, intend, may, will,
should, could, would and similar expressions are intended to identify
forward-looking statements. You should not place undue reliance on these
forward-looking statements. Our actual results could differ materially from
those anticipated in the forward-looking statements for many reasons, including
the risks described in this report, the risks described in our Annual Report on
Form 10-K for the year ended June 30, 2021 and other reports we file with the
Securities and Exchange Commission. Although we believe the expectations
reflected in the forward-looking statements are reasonable, they relate only to
events as of the date on which the statements are made. We do not intend to
update any of the forward-looking statements after the date of this report to
conform these statements to actual results or to changes in our expectations,
except as required by law.
Overview
We have been a developer and manufacturer of advanced optical instruments since
1982. Our medical instrumentation line includes traditional endoscopes and
endocouplers as well as other custom imaging and illumination products for use
in minimally invasive surgical procedures. Much of our recent development
efforts have been targeted at the development of next generation endoscopes. We
selectively execute internal research and development programs to develop next
generation capabilities for designing and manufacturing 3D endoscopes and very
small Microprecision lenses, anticipating future requirements as the surgical
community continues to demand smaller and more enhanced imaging systems for
minimally invasive surgery.
As Ross Optical Industries of El Paso, Texas we also operate as a supplier of
custom optical components and assemblies for military and defense, medical and
various other industrial applications. All products sold by us under the Ross
Optical name include a custom or catalog optic, which is sourced through our
extensive domestic and worldwide network of optical fabrication companies. Most
systems make use of optical lenses, prisms, mirrors and windows and range from
individual optical components to complex mechano-optical assemblies. Products
often include thin film optical coatings that are applied using our in-house
coating department.
As Lighthouse Imaging of Windham, Maine we also operate as a manufacturer of
advanced optical imaging systems and accessories. We have a strong expertise in
electrical engineering and development of end-to-end medical visualization
devices. Product development competencies at Lighthouse Imaging include Systems,
Optical, Mechanical, Electrical and Process Development Engineering. Our product
development team has extensive experience developing visualization systems that
are used in a variety of clinical applications. Lighthouse Imaging is an
industry leader in chip on tip visualization systems.
Approximately 34% our business during the nine months ended March 31, 2022 is
from engineering services primarily relating to the design of medical device
optical assemblies, 45% from the sale of both internally manufactured and
purchased optical components, and 21% from the manufacture of optical assemblies
and sub-assemblies primarily for medical device instrument applications. Our
proprietary medical instrumentation line, unique custom design and manufacturing
capabilities, and expert electrical engineering and development has generated
traditional proprietary endoscopes and endocouplers as well as other custom
imaging and illumination products for our customers' use in minimally invasive
surgical procedures. We design and manufacture 3D endoscopes and very small
Microprecision lenses, assemblies and complete medical devices to meet the
surgical community's continuing demand for smaller, disposable, and more
enhanced imaging systems for minimally invasive surgery.
15
We are registered to the ISO 9001:2015 and ISO 13485:2016 Quality Standards and
comply with the FDA Good Manufacturing Practices and the European Union Medical
Device Directive for CE marking of our medical products.
Our internet websites are www.poci.com, www.rossoptical.com, and
www.lighthouseoptics.com. Information on our websites is not intended to be
integrated into this report. Investors and others should note that we announce
material financial information using our company websites (www.poci.com;
www.rossoptical.com; www.lighthouseoptics.com), our investor relations website,
SEC filings, press releases, public conference calls and webcasts. Information
about Precision Optics, our business, and our results of operations may also be
announced by social media posts on our Ross Optical and Lighthouse LinkedIn
pages (www.linkedin.com/company/ross-optical-industries/)
(https://www.linkedin.com/company/lighthouse-imaging-corporation/) and Twitter
feed (http://twitter.com/rossoptical) and on our Lighthouse Facebook page
(https://www.facebook.com/lighthouseoptics/).
The information that we post on these social media channels could be deemed to
be material information. Therefore, we encourage investors, the media, and
others interested in Precision Optics to review the information that we post on
these social media channels. These social media channels may be updated from
time to time on Precision Optics investor relations website. The information on,
or accessible through, our websites and social media channels is not
incorporated by reference in this Quarterly Report on Form 10-Q.
The markets in which we do business are highly competitive and include both
foreign and domestic competitors. Many of our competitors are larger and have
substantially greater resources than we do. Furthermore, other domestic or
foreign companies, some with greater financial resources than we have, may seek
to produce products or services that compete with ours. We routinely outsource
specialized production efforts as required to obtain the most cost-effective
production. Over the years we have developed extensive experience collaborating
with other optical specialists worldwide.
We believe that our future success depends to a large degree on our ability to
develop new optical products and services to enhance the performance
characteristics and methods of manufacture of existing products. Accordingly, we
expect to continue to seek and obtain product-related design and development
contracts with customers and to selectively invest our own funds on research and
development, particularly in the areas of Microprecision optics, micro medical
cameras, illumination, single-use endoscopes and 3D endoscopes.
Current sales and marketing activities are intended to broaden awareness of the
benefits of our new technology platforms and our successful application of these
new technologies to medical device projects requiring surgery-grade
visualization from sub-millimeter sized devices and 3D endoscopy, including
single-use products and assemblies. We market directly to established medical
device companies primarily in the United States that we believe could benefit
from our advanced endoscopy visualization systems. Through this direct
marketing, referrals, attendance at trade shows and a presence in online
professional association websites, we have expanded our on-going pipeline of
projects to significant medical device companies as well as well-funded emerging
technology companies. We expect our customer pipeline to continue to expand as
development projects transition to production orders and new customer projects
enter the development phase. Our Ross Optical division markets through existing
customers and trade shows, in addition to proactive online marketing strategies
executed primarily through its website.
General
This management's discussion and analysis of financial condition and results of
operations is based upon our unaudited consolidated financial statements, which
have been prepared without audit, pursuant to the rules and regulations of the
Securities and Exchange Commission. The preparation of these consolidated
financial statements requires us to make estimates and judgments that affect the
reported amounts of assets, liabilities, revenues and expenses. We base our
estimates on historical experience and on various other assumptions that are
believed to be reasonable under the circumstances, the results of which form the
basis for making judgments about the carrying values of assets and liabilities
that are not readily apparent from other sources. Actual results may differ from
these estimates.
There have been no significant changes in our critical accounting policies as
disclosed in the Notes to our Financial Statements contained in our Annual
Report on Form 10-K for the year ended June 30, 2021 filed with the Securities
and Exchange Commission on September 28, 2021.
16
Results of Operations
Our total revenues for the quarter ended March 31, 2022, were $4,651,352, as
compared to $2,458,290 for the same period in the prior year, an increase of
$2,193,062, or 89.2%, primarily due to inclusion of the Lighthouse division
since its acquisition on October 4, 2021 and an increase in medical devise
manufacturing revenue. Excluding the effect of the Lighthouse acquisition,
engineering revenue experienced a slight quarter-over-quarter decrease while
production revenue was up 106% and component revenue increased 32% from the
quarter ended March 31, 2021 to 2022.
Our total revenues for the nine months ended March 31, 2022 were $10,884,737, as
compared to $8,001,641 for the same period in the prior year, an increase of
$2,883,096, or 36.0% primarily due to inclusion of the Lighthouse division since
its acquisition on October 4, 2021. Excluding the effect of the Lighthouse
acquisition, engineering revenue during the nine months ended March 31, 2022
decreased approximately $287,000 compared to the same period of the prior year
due primarily to a change in mix of engineering projects. Component revenues
increased approximately $543,000 during the nine months ended March 31, 2022
compared to the same period of the prior year, and production revenue increased
approximately $161,000 over the same period as production on some products began
to return to pre-pandemic levels.
Our largest customer during the three and nine months ended March 31, 2022
accounted for 10.9% and 9.0%, respectively, of our revenue and represented
manufacturing assembly revenues for a medical diagnostic system. We generated
revenues from 193 unique customers during the nine months ended March 31, 2022,
and one single customer accounted for slightly more than 10% or more of our
revenue for the quarter and no single customer accounted for 10% or more of our
revenue for the nine months ended March 31, 2022 or the fiscal year ended June
30, 2021.
The COVID-19 world-wide pandemic that began during the quarter ended March 31,
2020 and the domestic and international impact of policy decisions being made in
major countries around the world has had, and could continue to have, an adverse
impact on our sources of supply, current and future orders from our customers,
collection of amounts owed to us from our customers, our internal operating
procedures, and our overall financial condition. Given the uncertainty
surrounding the continuation of economic impacts both domestically and abroad,
we cannot predict with certainty at this time what the future impact of COVID-19
and resulting business and economic policies in the US and abroad will be on our
up-coming quarterly fiscal operating results.
Gross profit for the quarter ended March 31, 2022 was $1,728,209, compared to
$818,024 for the same period in the prior year, an increase of $910,185, or
111.3%. Gross profit for the quarter ended March 31, 2022 as a percentage of our
revenues was 37.2%, an increase from the gross profit percentage of 33.3% for
the same period in the prior year. Gross profit for the nine months ended
March 31, 2022 was $3,486,823, as compared to $2,647,642 for the same period in
the prior year, an increase of $839,181 or 31.7%. Gross profit for the nine
months ended March 31, 2022 as a percentage of our revenues was 32.0%, a
decrease from the gross profit percentage of 33.1% for the same period in the
prior year. Quarterly gross profit and gross profit percentage depend on a
number of factors, including overall sales volume, facility utilization, product
sales mix, the costs of engineering services, and production start-up costs and
challenges in connection with new products, the effects of COVID-19 pandemic
policy decisions on various economies and our suppliers and customers, as well
as the effects on production efficiencies due to the augmented policies we have
incorporated into our operations as a result of the COVID-19 pandemic.
Our gross margin on individual engineering projects is dependent on a number of
factors and is expected to fluctuate from quarter to quarter based on the nature
and status of engineering projects, unanticipated cost over-runs, design
challenges and changes, start-up production activities or other customer-imposed
project changes or delays. Our increase in gross margin dollars during the
quarter ended March 31, 2022 was due to inclusion of the Lighthouse division
since its acquisition on October 4, 2021, an increase in medical devise
manufacturing revenue, and improved efficiencies in engineering projects, which
is partially offset by inclusion of the Lighthouse division engineering and
production revenues at overall margins lower than the Ross Optical division
revenues. The remainder of our production, engineering and component revenues
resulted in margins within our targeted range with reasonably expected
fluctuations.
17
Research and development expenses were $214,898 for the quarter ended March 31,
2022, compared to $146,063 for the same period in the prior year, an increase of
$68,835, or 47.1%. Research and development expenses were $433,248 for the nine
months ended March 31, 2022, compared to $443,609 for the same period in the
prior year, a decrease of $10,361, or 2.3%. In-house research and development
and certain internal functions not directly related to customer engagements are
classified as research and development expenses with the majority of our
engineering, research and development activities being consumed in revenue
generating engagements with our customers for the development of their products.
During the quarter and nine months ended March 31, 2022 we had an increase in
research and development costs due to the inclusion of the Lighthouse division
offset by a greater amount of our engineering personnel time consumed in
customer focused compared to the same periods of the prior fiscal year.
Selling, general and administrative expenses were $1,574,432 for the quarter
ended March 31, 2022, compared to $927,979 for the same period in the prior
year, an increase of $646,453, or 69.7%. Selling, general and administrative
expenses were $3,974,824 for the nine months ended March 31, 2022, compared to
$2,671,176 for the same period in the prior year, an increase of $1,303,648, or
48.8%. The increase in selling, general and administrative expenses in the three
and nine months ended March 31, 2022 compared to the same periods of the prior
fiscal year was primarily due to inclusion of the Lighthouse division since its
acquisition on October 4, 2021, plus increased stock-based compensation and
marketing related expenses.
Liquidity and Capital Resources
We have sustained recurring net losses from operations for several years. During
the nine months ended March 31, 2022, we had a net loss of $1,197,713 and used
cash in operating activities of $879,967. At March 31, 2022, cash was $831,585,
accounts receivables were $3,347,692 and current liabilities were $5,770,887,
including $1,018,275 of customer advances received for future order deliveries.
Although our revenue and gross margin have increased due to the acquisition of
the Lighthouse division, our operating expenses have also increased, and we
continue to experience pricing pressure from our customers and challenges in
engineering projects and production orders that can result in cost over-runs and
depressed gross margins. We also experience added uncertainty related to our
vendors ability to supply materials and our customers future order levels as a
result of the economic impact the COVID-19 world-wide pandemic and related
jurisdictional policies and regulations and lingering supply-chain issues.
Consequently, critical to our ability to maintain our financial condition is
achieving and maintaining a level of quarterly revenues that generate break even
or better financial performance as well as timely collection of accounts
receivable from our customers. We believe profitable operating results can be
achieved through a combination of revenue levels, realized gross margins and
controlling operating expense increases, all of which are subject to periodic
fluctuations resulting from sales mix and the stage of completion of varying
engineering service projects as they progress towards and into production level
revenues.
We have traditionally funded working capital needs through product sales,
management of working capital components of our business, cash received from
public and private offerings of our common stock, warrants to purchase shares of
our common stock or convertible notes, manufacturing equipment leases, and by
customer advances paid against purchase orders by our customers and recorded in
the current liabilities section of the accompanying financial statements. We
have incurred year to year and quarter to quarter operating losses during our
efforts to develop current products including Microprecision optical elements,
micro medical camera assemblies and 3D endoscopes. Our management believes that
the opportunities represented by these technical capabilities and related
products have the potential to generate sales increases to achieve breakeven and
profitable results.
On October 4, 2021 we acquired the assets of Lighthouse Imaging, LLC as
described in note 2. Business Acquisition to the accompanying financial
statements in this Form 10-Q. To finance the cash portion of the acquisition
price we entered into a $2,600,000 bank term loan, sold shares of our common
stock for gross proceeds of $1,500,000. We also secured a $250,000 bank line of
credit from the same bank on October 4, 2021 for working capital needs, upon
which no borrowings are outstanding as of December 31, 2021.
18
Capital equipment expenditures and additional patent costs during the nine
months ended March 31, 2022 were $82,660. Future capital equipment and patent
expenditures will be dependent upon future sales and success of on-going
research and development efforts.
Contractual cash commitments for the fiscal periods subsequent to March 31,
2022, are summarized as follows:
Fiscal 2022 Thereafter Total
Capital lease for equipment, including
interest $ 12,155 $ 171,161 $ 183,316
Minimum operating lease payments - Ross
Optical division $ 15,705 $ 134,799 $ 150,504We have contractual cash commitments related to open purchase orders as of March
31, 2022 of approximately $1,263,003.
Off-Balance Sheet Arrangements
We currently have no off-balance sheet arrangements that have, or are reasonably
likely to have, a current or future material effect on our financial condition,
changes in financial condition, revenues or expenses, results of operations,
liquidity, capital expenditures or capital resources.
© Edgar Online, source Glimpses
PRECISION OPTICS CORPORATION, INC. 
